Excorim and COBE BCT sign distribution agreement with Therasorb

Excorim and COBE BCT sign distribution agreement with Therasorb Excorim, Lund, Sweden - a wholly owned subsidiary of COBE BCT - has signed an exclusive distribution agreement with Therasorb, Munich, Germany. Therasorb will exclusively sell Excorim's immunoadsorption products on markets within Western Europe, Africa and the Middle East. In addition, Therasorb will be a non-exclusive distributor for selected Therapeutic Apheresis products produced by Excorim. The parties may add other products and/or territories to the agreement from time to time. Stated COBE BCT President Edward C. Wood, "We are pleased to have Therasorb as a partner for our Excorim products. We have long been a leader in Therapeutic Apheresis and immunoadsorption products worldwide, and recognize the importance of having a dedicated effort in immunoadsorption to create a successful market." Stated Gustav Samuelsson, President of Excorim, "Having a strong marketing partner like Therasorb will allow us to concentrate our energies in future development to continue the success we have created today. This will create greater possibilities for the medical profession to treat severely ill patients." Stated Holger Beckmann, Marketing Manager, Therasorb, "We believe the Excorim products will be a powerful, complimentary product line to our current products. We believe that by combining Excorim's Protein-A columns and monitors with those of our own, we will have the synergy needed to create greater market success." For further information: Edward C. Wood, President, COBE BCT Inc., phone +1-303-232 6800 Gustav Samuelsson, President, Excorim AB, phone +46-46-16 97 00, +46-708-339180 Holger Beckmann, Marketing Manager, Therasorb, phone +49-89-32 18 360, +49-171-356 4031 Excorim is a company in Gambro specializing in extracorporeal immunoadsorption and therapeutic apheresis for the treatment of autoimmune diseases and immunized conditions. COBE BCT is a Gambro company specializing in apheresis procedures in Transfusion Medicine, Therapeutic Apheresis, and Stem Cell Therapy. Gambro is an international medical-technology group with revenues of approximately SEK 18 billion and about 17,000 employees in some 40 countries. Therasorb is a privately owned company with focus on extracorporeal immunoadsorption and therapeutic apheresis for the treatment of autoimmune diseases and immunized conditions as well as treatment of hypercholesterolemia.